A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
-
Published:2019-08
Issue:8
Volume:30
Page:1279-1288
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Author:
Loibl S.ORCID, Untch M., Burchardi N., Huober J., Sinn B.V., Blohmer J.-U., Grischke E.-M., Furlanetto J., Tesch H., Hanusch C., Engels K., Rezai M., Jackisch C., Schmitt W.D., von Minckwitz G., Thomalla J., Kümmel S., Rautenberg B., Fasching P.A., Weber K., Rhiem K., Denkert C., Schneeweiss A.
Subject
Oncology,Hematology
Reference22 articles.
1. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial;von Minckwitz;Lancet Oncol,2014 2. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial;Hahnen;JAMA Oncol,2017 3. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial;Untch;Lancet Oncol,2016 4. A Schneeweiss, C Jackisch, S Schmatloch et al. Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer – GBG69 [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium, 2017 Dec 5–9, San Antonio, TX. Philadelphia, PA: AACR, Cancer Res 2018; 78(Suppl 4):Abstract nr GS3–05. 5. Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC);Adams;Oncoimmunology,2015
Cited by
487 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|